Platelet GP IIb/IIIa receptor inhibitors in diabetics undergoing PCI using stents

We examined the outcomes of the diabetic population in the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) to test whether clinical outcomes with tirofiban were similar to abciximab. Glycoprotein (GP) IIb/IIIa inhibition with tirofiban and abciximab was largely associated with similar clinical outcomes in this important patient subset. The similar rates of 6-month target-vessel revascularization and 1-year mortality in the two treatment groups suggest that the non-GP IIb/IIIa actions of abciximab are not associated with an appreciable clinical benefit in diabetic patients.